Skip to content

Willdan Group WLDN Pro Forma Weighted Average Shares Outstanding Diluted

Pro Forma Weighted Average Shares Outstanding Diluted at other companies

Evommune
 logo
Evommune EVMN
85.1M+1,171%
Evommune
 logo
Evommune EVMN
85.1M+1,171%
Curtiss-Wright logo
Curtiss-WrightCW
37.1M-2.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
107.7M-3.1%
Robinhood Markets, Inc. logo
Robinhood Markets, Inc.HOOD
915M+0.6%
IonQ logo
IonQIONQ
371.2M+62.3%

Other financials

Income statement

See full
Revenue$155.1M+1.8%
Gross profit$63.2M+9.5%
Operating income$7.3M+3.6%
Net income$8.5M+82.0%
EPS (diluted)$0.55+71.9%

Balance sheet

See full
Cash & equivalents$28.3M-26.3%
Total debt$68.2M-33.6%
Total equity$310.3M+26.4%
Total assets$511.7M+8.6%

Cash flow

See full
Operating cash flow-$24.4M-836%
CapEx$2.0M-12.4%
Free cash flow-$26.4M-2,736%

Valuation

See full
Market cap$1.22B+45.7%
Enterprise value$1.26B+39.7%
P/E21.6×-12.8×
P/S1.8×+0.4×

Profitability

See full
Gross margin38.2%+2.4pp
Operating margin6.5%+0.9pp
Net margin8.2%+4.2pp
FCF margin6.3%-0.5pp

Returns & leverage

See full
Return on equity20.3%+9.5pp
Debt / equity0.2×-0.2×
Current ratio1.7×+0.1×

Where this comes from

Reported directly by Willdan Group in its filing.

Tagged under the XBRL concept us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted.

The official record: Willdan Group’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Willdan Group's pro forma weighted average shares outstanding diluted.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Willdan Group's pro forma weighted average shares outstanding diluted?
Willdan Group (WLDN) reported pro forma weighted average shares outstanding diluted of 15.1M in Q4 2025.
What does pro forma weighted average shares outstanding diluted mean?
This metric indicates the weighted average number of shares outstanding, including the dilutive impact of potential common stock equivalents, adjusted for the pro forma effects of business acquisitions. It serves as the denominator for diluted pro forma earnings per share calculations. This provides a consistent basis for comparing the company's capital structure and earnings power after accounting for recent acquisitions.